Johnson & Johnson Press Release

NEW BRUNSWICK, N.J. – April 24, 2026 – Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Atraverse Medical, Inc., a privately-held medical device company pioneering next-generation left-heart access and radiofrequency (RF) technology.

Achieving safe and precise access to the left atrium remains one of the most critical steps in atrial fibrillation ablation. Atraverse Medical’s HOTWIRE™ Transseptal Access System, already used in nearly 3,000 clinical procedures, is an FDA-cleared RF guidewire and generator system that is designed for greater confidence and control when accessing the left atrium. The system offers multiple innovative features—including impedance-sensing automatic energy shutoff, compatibility with multiple sheaths, and clear tip visibility under intracardiac echocardiography—that support smooth and efficient access to the left atrium.

The planned acquisition of Atraverse Medical would strengthen Johnson & Johnson’s portfolio of cardiac ablation solutions, bringing electrophysiologists innovative tools to treat patients with atrial fibrillation and other cardiac arrhythmias. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Financial terms of the transaction are not being disclosed.